贤丰控股股份有限公司 2024年度独立董事述职报告 （邓延昌） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"、"贤 丰控股"）的独立董事，根据《上市公司独立董事管理办法》以及《独立董事工 作制度》的规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人邓延昌，教授级高级工程师，曾任辽宁有色地质勘查总院院长、国家危 机矿山接替资源勘查监审专家、银泰黄金股份有限公司（000975.SZ）独立董事。 2020年1月23日起任公司独立董事，无其他兼职情况。 本人不在贤丰控股担任其他职务，与贤丰控股及其主要股东不存在直接或间 接利害关系，或者其他可能影响本人独立性的关系，满足有关规定中对于出任贤 丰控股独立董事所应具备的独立性要求。 二、年度履职概况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席3次，以线上会议方 式出席1次；公司召开董事会会议13次，本人以现场方式出席5次，以线上会议方 式出席8次；均无委托出席和缺席情形，本人对提交董事会审议的各项议案均表 示同意，无反对或弃权情形。 （五）与中小投资者沟通交流情况 （二）参与董事会专门委员会、独 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （肖世练） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"或 "贤丰控股"）的独立董事，根据《上市公司独立董事管理办法》及《独立董 事工作制度》等相关规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人肖世练，博士研究生学历，中国注册会计师，国际注册内部审计师。 曾供职于广州海关、普华永道会计师事务所、安永会计师事务所、广州农村商 业银行股份有限公司、粤港澳大湾区产融投资有限公司，现任职于广州健博企 业服务有限公司，兼任蜂助手股份有限公司（301382.SZ）、深圳市佳士科技股 份有限公司（300193.SZ）、深圳市新涛新材料股份有限公司、深圳市皓吉达电 子科技股份有限公司的独立董事，2023年10月9日起任公司独立董事。 本人不在贤丰控股担任除独立董事外的其他职务，与贤丰控股及其主要股 东不存在直接或间接利害关系，或者其他可能影响本人独立性的关系，满足有 关规定中对于出任贤丰控股独立董事所应具备的独立性要求。 二、年度履职情况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席1次，以线上 ...

Financial Performance - The company's operating revenue for 2024 was ¥440,478,600.49, representing a 400.31% increase compared to ¥88,040,600.80 in 2023[20]. - The net profit attributable to shareholders for 2024 was -¥113,006,166.29, a slight improvement of 5.92% from -¥120,115,833.29 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥479,582,657.09, a significant decline of 818.32% compared to -¥52,224,007.16 in 2023[20]. - Total assets at the end of 2024 reached ¥1,470,823,932.83, an increase of 23.33% from ¥1,192,593,505.11 at the end of 2023[20]. - The company's net assets attributable to shareholders decreased by 20.44% to ¥820,299,187.95 at the end of 2024 from ¥1,031,077,872.65 at the end of 2023[20]. - Non-recurring gains for 2024 amounted to ¥18,295,621.80, compared to ¥12,380,814.32 in 2023, primarily from asset disposals and government subsidies[25][26]. - The company's basic earnings per share for 2024 was -¥0.1045, a slight improvement of 1.32% from -¥0.1059 in 2023[20]. - The total amount of accounts receivable confirmed during the reporting period was ¥6,737.57 million[52]. - The company's total operating costs reached ¥405,224,302.75, a significant increase of 688.43% compared to the previous year[55]. - The total distributable profit for the reporting period was -419,349,894.07 CNY, indicating a loss[130]. Business Operations - The main business operations include veterinary vaccines, copper-clad laminates, and animal nutrition (feed) as of the report date[18]. - The company has strategically exited the fine enameled wire business as of the end of Q3 2022, focusing on its new business segments[18]. - The animal nutrition business has seen monthly sales growth due to increased market demand, despite being in its early development stage with only 2 months of operational experience[34]. - The company has established a comprehensive procurement management system to reduce costs while ensuring stable quality, adapting to market changes[33]. - The company is focusing on enhancing product quality, optimizing sales channels, and improving production capacity to better its profitability[36]. - The company has implemented a strategic transformation to improve operational conditions and expand its business scope, aiming to eliminate delisting risk warnings[43]. - The company has upgraded its production facilities to meet the latest GMP standards, ensuring the safety, effectiveness, and quality stability of its vaccines[39]. - The company aims to position itself as a "vaccine process expert and disease solution expert," focusing on high-quality vaccine production and comprehensive technical services for livestock farms[40]. Market Conditions - The company reported a significant decline in the pig farming industry, with a 3.31% decrease in the national pig slaughter volume to 703 million heads in 2024[28]. - The average price of pigs showed signs of recovery starting in Q2 2024, but this did not translate to improved conditions for upstream animal health companies[28]. - The company faced intense competition in the animal health sector, with price wars becoming the norm due to prolonged payment cycles and low bidding standards[28]. - The pig vaccine business has faced increased competition, leading to a decline in product gross margins and longer accounts receivable periods[33]. - The feed industry is evolving towards green and intelligent production in response to environmental policies and customized demands[29]. Research and Development - The company has established a comprehensive innovation system through collaborations with top research institutions, resulting in 9 new veterinary drug registration certificates and 33 invention patents[37]. - A new live vaccine for pseudorabies (JS-A1 strain) developed in collaboration with the Chinese Academy of Agricultural Sciences received a new veterinary drug certificate in November 2024, marking it as the first of its kind in China[38]. - The company has a total of 31 vaccine products registered, including 15 for pigs and 16 for poultry, and continues to enhance its product offerings to strengthen market competitiveness[39]. - R&D investment increased by 28.89% to ¥15,564,041.87 in 2024, while the proportion of R&D investment to operating revenue decreased to 3.53% from 13.72%[63]. - The number of R&D personnel rose by 29.55% to 57 in 2024, with a significant increase in master's degree holders by 41.18%[63]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations and decision-making processes[97]. - The board of directors consists of 7 members, including 3 independent directors, meeting regulatory requirements for governance[98]. - The company has implemented a strategic plan to enhance market competitiveness and is committed to ongoing innovation in response to industry trends and customer needs[90]. - The company has established a comprehensive investor relations management system to enhance communication and ensure investors' rights are protected[99]. - The company has implemented a public opinion response management system to effectively handle various public sentiments impacting stock prices and business reputation[99]. Environmental Compliance - The company has complied with all relevant environmental protection laws and regulations during its operations[141]. - The total investment in environmental protection measures for 2024 by Shiji Biological amounted to CNY 268,360, including wastewater treatment agents, environmental taxes, hazardous waste disposal, and equipment maintenance[150]. - The companies are actively complying with local environmental regulations and have established measures to manage and monitor their emissions[145]. - Shiji Biological successfully executed its environmental self-monitoring plan during the reporting period without any exceedances[147]. Shareholder Relations - The company reported a profit distribution plan of 0 cash dividends and 0 bonus shares per 10 shares for all shareholders[5]. - The company did not propose any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[132]. - The company plans to maintain its share repurchase strategy in 2024 but will not distribute cash dividends or issue bonus shares[132]. - The participation rate for the 2024 first extraordinary shareholders' meeting was 40.17%[102]. - The company completed the repurchase of 101,720,721 shares, accounting for 8.96% of the total share capital, which is treated as a cash dividend[128]. Risks and Challenges - The company has faced a decline in its veterinary vaccine business for two consecutive years, with sales at a low level, indicating high market competition risks[89]. - The company is addressing raw material price volatility risks, which could significantly impact costs and profits, by closely monitoring market trends and exploring strategic supplier relationships[92]. - The company has a high customer concentration in its feed business, which poses risks if customer relationships deteriorate; it plans to actively develop new markets to mitigate this risk[91]. - The company emphasizes the importance of managing accounts receivable to prevent bad debt risks as its business scales up, despite currently having a low bad debt rate[93]. Audit and Compliance - The company received a standard unqualified audit report for the 2024 fiscal year, with audited revenue exceeding 300 million yuan[188]. - The 2023 audit report highlighted concerns regarding the controlling shareholder's bankruptcy proceedings, which have since been addressed, ensuring no significant impact on the company's operations[187]. - The company identified and corrected significant internal control deficiencies related to revenue recognition and inflated income from subsidiary Chengdu Shiji Bio-Pharmaceutical Co., Ltd., with corrections made prior to the annual report[189][190]. - The company has implemented measures to strengthen internal controls, including revising organizational structures and enhancing management oversight to prevent future issues[191].

[Key Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) In Q1 2025, the company achieved significant revenue and net profit growth, primarily from new businesses and asset disposal, despite negative core business profitability and operating cash flow [Key Accounting Data and Financial Indicators](index=1&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Key Financial Indicators for Q1 2025 | Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 294,682,212.25 | 16,649,876.31 | 1,669.88% | | Net Profit Attributable to Shareholders (RMB) | 14,210,084.66 | -153,837.59 | 9,337.07% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) (RMB) | -3,456,542.95 | -8,687,680.76 | 60.21% | | Net Cash Flow from Operating Activities (RMB) | -70,936,119.71 | 10,809,362.41 | -756.25% | | Basic Earnings Per Share (RMB/share) | 0.0138 | -0.0001 | 13,900.00% | | Total Assets (RMB) | 1,475,871,009.94 | 1,470,823,932.83 | 0.34% (vs. end of prior year) | | Total Equity Attributable to Shareholders (RMB) | 835,229,144.34 | 820,299,187.95 | 1.82% (vs. end of prior year) | [Non-recurring Gains and Losses Items and Amounts](index=1&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20%E9%9D%9E%E5%B8%B8%E9%87%91%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) - Total non-recurring gains and losses for the current period amounted to **RMB 17.67 million**, a key factor for the company's profitability, with non-current asset disposal gains contributing **RMB 18.49 million**, primarily from the sale of Zhuhai factory land and technology contract transfer[4](index=4&type=chunk)[5](index=5&type=chunk) Details of Non-recurring Gains and Losses Items | Item | Amount for Current Period (RMB) | Description | | :--- | :--- | :--- | | Non-current asset disposal gains and losses | 18,488,785.48 | Primarily due to partial completion of Zhuhai factory land transfer and Chengdu Shiji technology contract transfer | | Government grants recognized in current profit/loss | 721,156.49 | - | | Other non-operating income/expenses and fair value changes | 38,032.59 | - | | Impact on minority interests (after tax) | 1,581,346.95 | - | | **Total** | **17,666,627.61** | **--** | [Changes and Reasons for Key Accounting Data and Financial Indicators](index=2&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) - Significant increases in operating revenue and costs (**1669.88%** and **3624.62%** respectively) were primarily driven by the newly added copper-clad laminate and feed businesses in the current period[6](index=6&type=chunk) - Research and development expenses increased by **118.63%** year-on-year, mainly due to increased R&D investment in Gaoshuo Hangyu's copper-clad laminate business[6](index=6&type=chunk) - Net cash flow from operating activities significantly decreased by **756.25%**, primarily impacted by the credit terms of subsidiary Gaoshuo Hangyu[7](index=7&type=chunk) - Net cash flow from investing activities turned positive, increasing by **159.72%**, mainly due to the recovery of investment funds and redemption of wealth management products in the current period[7](index=7&type=chunk) [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) As of the reporting period end, the company had 28,097 common shareholders, with the top two holding over 30%, and the second largest shareholder's entire stake is pledged and frozen [Common Shareholder Holdings](index=3&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) - As of the end of the reporting period, the total number of common shareholders was **28,097**[9](index=9&type=chunk) Top Two Shareholders' Holdings | Shareholder Name | Shareholding Percentage (%) | Number of Shares Held | Share Status | | :--- | :--- | :--- | :--- | | Shenzhen Ansheng Zhihe Investment Partnership (Limited Partnership) | 19.18% | 198,140,000 | N/A | | Xianfeng Holdings Group Co., Ltd. | 11.05% | 114,152,000 | Pledged 69,000,000; Frozen 114,152,000 | - The second largest shareholder, Xianfeng Holdings Group Co., Ltd., has **114,152,000** shares (**11.05%** of total share capital) fully frozen, with **69,000,000** shares pledged[9](index=9&type=chunk) [Other Significant Matters](index=4&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company disclosed significant matters including office address changes, asset transfer progress, and a CSRC administrative penalty pre-notification, which may impact operations and stock price Significant Matters Disclosed During the Reporting Period | Overview of Significant Matter | Disclosure Date | | :--- | :--- | | Change of Office Address | 2025年01月24日 | | Progress and Extension of Land Use Rights and Above-Ground Building Ownership Transfer | 2025年02月13日, 2025年03月22日 | | Receipt of Pre-notification of Administrative Penalty | 2025年03月24日 | [Quarterly Financial Statements](index=4&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the unaudited Q1 2025 consolidated financial statements, showing slight asset growth, liability decrease, significant revenue and profit turnaround from new businesses and non-recurring gains, and deteriorating operating cash flow despite improved investing and financing cash flows - The company's first quarter report is unaudited[19](index=19&type=chunk) [Consolidated Balance Sheet](index=4&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Key Balance Sheet Items Changes | Item | Period-end Balance (RMB) | Period-start Balance (RMB) | | :--- | :--- | :--- | | Total Assets | 1,475,871,009.94 | 1,470,823,932.83 | | Total Liabilities | 589,800,602.42 | 599,813,408.35 | | Total Equity Attributable to Parent Company Owners | 835,229,144.34 | 820,299,187.95 | [Consolidated Income Statement](index=6&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Key Income Statement Items | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | I. Total Operating Revenue | 294,682,212.25 | 16,649,876.31 | | II. Total Operating Costs | 293,560,627.82 | 25,970,020.19 | | III. Operating Profit | 14,309,681.85 | -1,911,435.81 | | V. Net Profit | 14,340,011.31 | -1,511,035.74 | | Net Profit Attributable to Parent Company Owners | 14,210,084.66 | -153,837.59 | [Consolidated Cash Flow Statement](index=8&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Key Cash Flow Statement Items | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -70,936,119.71 | 10,809,362.41 | | Net Cash Flow from Investing Activities | 16,264,345.28 | -27,236,522.83 | | Net Cash Flow from Financing Activities | 14,437,996.31 | -5,022,735.16 | | Net Increase in Cash and Cash Equivalents | -40,171,026.63 | -21,117,345.36 |

Core Viewpoint - ST Xianfeng Holdings Co., Ltd. is facing potential delisting risks due to negative net profits and insufficient revenue, as indicated in their recent announcements and performance forecasts [2][3]. Group 1: Risk of Delisting - The company issued its sixth risk warning regarding potential delisting, as required by the Shenzhen Stock Exchange rules, following a negative net profit for the fiscal year 2023 and revenue below 100 million yuan [2][3]. - The stock will be under delisting risk warning starting April 29, 2024, due to the aforementioned financial performance [2]. - The company is currently undergoing its 2024 annual report preparation, and the final audited revenue figures will determine if the delisting risk warning can be lifted [3]. Group 2: Legal and Compensation Issues - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) due to violations related to information disclosure and false statements, which may lead to civil compensation claims from affected investors [4][9]. - Investors who purchased shares between April 28, 2023, and April 25, 2024, and sold or held them after April 26, 2024, may be eligible for compensation [6]. Group 3: Financial Performance Forecast - The company anticipates negative total profit, net profit, and net profit after deducting non-recurring gains and losses for the fiscal year 2024, with projected revenue between 340 million and 440 million yuan [3]. - The final audited revenue must exceed 300 million yuan for the company to avoid further delisting risks, subject to the approval of the Shenzhen Stock Exchange [3].

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-022 贤丰控股股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1. 根据《深圳证券交易所股票上市规则》(2024 年修订）第 9.3.6 条的规 定，公司应当在股票交易被实施退市风险警示当年会计年度结束后一个月内，披 露股票可能被终止上市的风险提示公告，在首次风险提示公告披露后至年度报告 披露前，每十个交易日披露一次风险提示公告。本次公告为公司第六次风险提示 公告，敬请广大投资者理性投资，注意投资风险。 2. 公司于 2024 年 4 月 26 日披露了《关于公司股票交易实施退市风险警示 和其他风险警示暨停复牌公告》（公告编号：2024-036），因公司 2023 年度归 属于上市公司股东的净利润为负值且扣除后营业收入低于 1 亿元，根据《深圳证 券交易所股票上市规则》（2023 年 8 月修订）相关规定，公司股票于 2024 年 4 月 29 日起被实施退市风险警示。若公司 2024 年度出现《深圳证券交易所股票上 市规则 ...

一、2023 年度审计报告非标审计意见涉及事项影响的消除情况 证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-021 贤丰控股股份有限公司 关于 2024 年年度报告编制及审计进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（以下简称"贤丰控股"）根据《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》的 相关规定，公司应当分别在年度报告预约披露日前二十个交易日和十个交易日， 披露年度报告编制及最新审计进展情况，相关情况如下： 1、关于带强调事项段的无保留意见审计报告所涉及事项 公司 2023 年度财务报告被北京兴华会计师事务所（特殊普通合伙）（以下 简称"兴华所"）出具了带强调事项段的无保留意见审计报告，相关强调事项段 提示投资者关注公司控股股东及其一致行动人存在影响公司控制权的事项、公司 股票存在因触及财务类强制退市条件被实施退市风险警示的情形。 截至本公告披露日，由于公司控股股东及其一致行动人积极寻求保持控制权 稳定的解决方案，其破产清算事项不影响公司正常生产经营 ...

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-020 贤丰控股股份有限公司 关于公司股份被公开拍卖完成过户的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（简称"公司"）控股股东贤丰控股集团有限公司（简 称"贤丰集团"）及其一致行动人广东贤丰控股有限公司（简称"广东贤丰"） 持有的公司 5,400 万股股票在京东拍卖平台上进行公开拍卖，其中：2,900 万股、 2,500 万股已经先后有竞拍结果、被裁定过户，4,500 万股已完成过户，近日公 司通过中国证券登记结算有限责任公司系统获悉，前述 5,400 万股中的 900 万股 已完成过户登记手续，现将有关进展情况公告如下： 一、股份拍卖情况 贤丰集团及其一致行动人广东贤丰持有的公司 5,400 万股股票在京东拍卖 平台上进行公开拍卖，买受人朱兴虎、吴宪彬分别竞得贤丰集团持有的公司股票 1,000 万股、1,000 万股，买受人吴宪彬竞得广东贤丰持有的公司股票 900 万股， 买受人陈新熊、江西鑫余环境科技有限公司分别竞得贤丰集团持有的公司股票 1,389 ...

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-018 | | 是否适用 | | --- | --- | | 具体情形 | （对可能触及的打 | | | 勾） | | 经审计的利润总额、净利润、扣除非经常性损益后的净 | | | 利润三者孰低为负值，且扣除后的营业收入低于 3 亿 | √ | | 元。 | | | 经审计的期末净资产为负值。 | | 贤丰控股股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1. 根据《深圳证券交易所股票上市规则》(2024 年修订）第 9.3.6 条的规 定，公司应当在股票交易被实施退市风险警示当年会计年度结束后一个月内，披 露股票可能被终止上市的风险提示公告，在首次风险提示公告披露后至年度报告 披露前，每十个交易日披露一次风险提示公告。本次公告为公司第五次风险提示 公告，敬请广大投资者理性投资，注意投资风险。 2. 公司于 2024 年 4 月 26 日披露了《关于公司股票交易实施退市风险警示 和其他风险警示暨停复牌公告》（公告编号：202 ...

证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-019 贤丰控股股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 贤丰控股股份有限公司（简称"公司"）于 2024 年 6 月 27 日召开第八届董 事会第十次会议审议通过了《关于回购股份用于股权激励的议案》，于 2024 年 6 月 28 日发布了《回购报告书》，董事会同意公司使用自有资金以集中竞价交 易方式回购公司股份，本次回购股份将用于实施股权激励，拟用于回购的资金总 额不低于人民币 3,000 万元（含），不超过人民币 6,000 万元（含），回购期限 为自董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详见公司 2024 年 6 月 28 日、2024 年 6 月 29 日披露于巨潮资讯网（www.cninfo.com.cn） 上的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，每个月的前三个交易日内披露截至上月末的回 购进展情况，现将具体情况公告如下： 一、回购公司股 ...